Aurinia Pharmaceuticals Increases 2023 Revenue Guidance Range From $135M-$155M To $150M-$160M From Net Product Sales Of LUPKYNIS (voclosporin)
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals has increased its 2023 revenue guidance range from $135M-$155M to $150M-$160M, due to net product sales of LUPKYNIS (voclosporin).
August 04, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurinia Pharmaceuticals' increased revenue guidance for 2023, driven by LUPKYNIS sales, may positively impact its stock price.
Aurinia Pharmaceuticals' increased revenue guidance indicates strong sales performance of LUPKYNIS, which is a positive signal to investors. This could lead to increased investor confidence and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100